Should I buy or sell TransCode Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransCode Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNAZ shares. View RNAZ analyst ratings or view top-rated stocks .

What is TransCode Therapeutics' stock price target for 2024?

1 equities research analysts have issued 12 month target prices for TransCode Therapeutics' shares. Their RNAZ share price targets range from $480.00 to $480.00. On average, they anticipate the company's stock price to reach $480.00 in the next year. This suggests a possible upside of 98,869.1% from the stock's current price. View analysts price targets for RNAZ or view top-rated stocks among Wall Street analysts .

How have RNAZ shares performed in 2024?

TransCode Therapeutics' stock was trading at $6.5920 on January 1st, 2024. Since then, RNAZ stock has decreased by 92.6% and is now trading at $0.4850. View the best growth stocks for 2024 here .

Are investors shorting TransCode Therapeutics?

TransCode Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 40,000 shares, a drop of 77.1% from the March 15th total of 174,800 shares. Based on an average daily trading volume, of 635,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.6% of the shares of the company are sold short. View TransCode Therapeutics' Short Interest .

When is TransCode Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RNAZ earnings forecast .

How were TransCode Therapeutics' earnings last quarter?

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) released its earnings results on Tuesday, November, 14th. The company reported ($67.20) EPS for the quarter, missing analysts' consensus estimates of ($60.00) by $7.20.

When did TransCode Therapeutics' stock split?

TransCode Therapeutics shares reverse split on the morning of Tuesday, January 16th 2024. The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did TransCode Therapeutics IPO?

TransCode Therapeutics (RNAZ) raised $25 million in an IPO on Friday, July 9th 2021. The company issued 6,250,000 shares at a price of $4.00 per share.

How do I buy shares of TransCode Therapeutics?

Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RNAZ

TransCode Therapeutics (RNAZ) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free RNAZ Stock Alerts

$0.48

-0.02 (-3.96%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.48
▼
$0.50
50-Day Range: $0.49
▼
$0.73
52-Week Range: $0.47
▼
$356.00

Volume: 112,982 shs
Average Volume: 329,816 shs
Market Capitalization: $2.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $480.00

Get TransCode Therapeutics alerts:

TransCode Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 98,869.1% Upside
$480.00 Price Target
Short Interest: Healthy
0.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.16
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.14) to ($0.67) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.79 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
TransCode Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
TransCode Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.61% of the float of TransCode Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
TransCode Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TransCode Therapeutics has recently decreased by 77.12%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
TransCode Therapeutics does not currently pay a dividend.
Dividend Growth
TransCode Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RNAZ.

2.3

News and Social Media Coverage

News Sentiment
TransCode Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for TransCode Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 6 people have searched for RNAZ on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
MarketBeat Follows
3 people have added TransCode Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TransCode Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.47% of the stock of TransCode Therapeutics is held by insiders.

1.3

Earnings and Valuation

Earnings Growth
Earnings for TransCode Therapeutics are expected to grow in the coming year, from ($2.14) to ($0.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TransCode Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TransCode Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TransCode Therapeutics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About TransCode Therapeutics Stock (NASDAQ:RNAZ)

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

RNAZ Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RNAZ Stock News Headlines

April 17, 2024 | uk.investing.com

FDA clears TransCode's drug trial for advanced tumors

April 17, 2024 | americanbankingnews.com

TransCode Therapeutics (NASDAQ:RNAZ) Receives "Buy" Rating from HC Wainwright

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 15, 2024 | globenewswire.com

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

April 4, 2024 | markets.businessinsider.com

Promising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode Therapeutics

April 3, 2024 | globenewswire.com

TransCode Therapeutics Reports 2023 Results; Provides Business Update

March 30, 2024 | uk.investing.com

TransCode Therapeutics appoints new Chief Medical Officer

March 29, 2024 | markets.businessinsider.com

TransCode Appoints Daniel Vlock As CMO

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 28, 2024 | finanznachrichten.de

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

March 28, 2024 | globenewswire.com

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

March 11, 2024 | finanznachrichten.de

TransCode Therapeutics, Inc.: TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

March 11, 2024 | globenewswire.com

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

March 6, 2024 | globenewswire.com

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

February 20, 2024 | finance.yahoo.com

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

February 20, 2024 | globenewswire.com

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

February 1, 2024 | uk.investing.com

Transcode Therapeutics Inc (RNAZ)

January 31, 2024 | finance.yahoo.com

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market

January 30, 2024 | benzinga.com

Looking Into TransCode Therapeutics's Recent Short Interest

January 29, 2024 | markets.businessinsider.com

TransCode Collaborates With Debiopharm; Financial Terms Not Disclosed

January 29, 2024 | finance.yahoo.com

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

January 22, 2024 | finance.yahoo.com

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

January 19, 2024 | msn.com

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session

January 18, 2024 | marketwatch.com

TransCode Therapeutics Shares Slide to 52-Week Low on Planned Public Offering

January 18, 2024 | finance.yahoo.com

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

January 15, 2024 | finanznachrichten.de

TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

January 14, 2024 | benzinga.com

TransCode Therapeutics Stock (NASDAQ:RNAZ) Dividends: History, Yield and Dates

See More Headlines

Receive RNAZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RNAZ
CUSIP: N/A
CIK: 1829635
Web: www.transcodetherapeutics.com
Phone: 857-837-3099
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $480.00
High Stock Price Target: $480.00
Low Stock Price Target: $480.00
Potential Upside/Downside: +98,869.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($774.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,550,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -934.78%
Return on Assets: -276.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.28
Quick Ratio: 1.28

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.62 per share
Price / Book: 0.19

Miscellaneous

Outstanding Shares: 5,810,000
Free Float: 5,723,000
Market Cap: $2.82 million
Optionable: Not Optionable
Beta: -0.35

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Thomas A. Fitzgerald M.B.A. (Age 72)
Interim CEO, CFO, President, VP of Administration & Director
Comp: $358.14k
Dr. Philippe P. Calais Ph.D. (Age 65)
Pharm., Pharm.D., Executive Chairman of the Board
Comp: $102.5k
Dr. Zdravka Medarova Ph.D. (Age 49)
Co-Founder & Chief Scientific Officer
Dr. Anna Moore Ph.D. (Age 62)
Co-Founder, Scientific Advisor & Member of Scientific Advisory Board
Ms. Susan Duggan M.B.A.
R.N., Senior Vice President of Operations
Dr. Daniel R. Vlock M.D. (Age 72)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RNAZ Stock Analysis - Frequently Asked Questions

Should I buy or sell TransCode Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransCode Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNAZ shares.
View RNAZ analyst ratings or view top-rated stocks.
What is TransCode Therapeutics' stock price target for 2024?: 1 equities research analysts have issued 12 month target prices for TransCode Therapeutics' shares. Their RNAZ share price targets range from $480.00 to $480.00. On average, they anticipate the company's stock price to reach $480.00 in the next year. This suggests a possible upside of 98,869.1% from the stock's current price.
View analysts price targets for RNAZ or view top-rated stocks among Wall Street analysts.
How have RNAZ shares performed in 2024?: TransCode Therapeutics' stock was trading at $6.5920 on January 1st, 2024. Since then, RNAZ stock has decreased by 92.6% and is now trading at $0.4850.
View the best growth stocks for 2024 here.
Are investors shorting TransCode Therapeutics?: TransCode Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 40,000 shares, a drop of 77.1% from the March 15th total of 174,800 shares. Based on an average daily trading volume, of 635,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.6% of the shares of the company are sold short.
View TransCode Therapeutics' Short Interest.
When is TransCode Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RNAZ earnings forecast.

How were TransCode Therapeutics' earnings last quarter?: TransCode Therapeutics, Inc. (NASDAQ:RNAZ) released its earnings results on Tuesday, November, 14th. The company reported ($67.20) EPS for the quarter, missing analysts' consensus estimates of ($60.00) by $7.20.
When did TransCode Therapeutics' stock split?: TransCode Therapeutics shares reverse split on the morning of Tuesday, January 16th 2024. The 1-40 reverse split was announced on Tuesday, January 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
When did TransCode Therapeutics IPO?: TransCode Therapeutics (RNAZ) raised $25 million in an IPO on Friday, July 9th 2021. The company issued 6,250,000 shares at a price of $4.00 per share.
How do I buy shares of TransCode Therapeutics?: Shares of RNAZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNAZ) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial